ChiCTR2000029907 版本V1.0 版本创建时间2020/02/16 19:41:59 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000029907 

最近更新日期:

Date of Last Refreshed on:

2020-02-16 19:40:37 

注册时间:

Date of Registration:

2020-02-16 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

新型冠状病毒(COVID-19)感染临床风险预警模型的构建与评价

Public title:

Study for construction and assessment of early warning score of the clinical risk of novel coronavirus infected patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

新型冠状病毒感染临床风险预警模型的构建与评价

Scientific title:

Study for construction and assessment of early warning score of the clinical risk of novel coronavirus infected patients (COVID-19)

研究课题代号(代码):

Study subject ID:

2020YFS0009

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

姚蓉 

研究负责人:

姚蓉 

Applicant:

Yao, Rong 

Study leader:

Yao, Rong 

申请注册联系人电话:

Applicant telephone:

+86 18980601415

研究负责人电话:

Study leader's telephone:

+86 18980601415

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1037070596@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1037070596@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省成都市国学巷37号四川大学华西医院

研究负责人通讯地址:

四川省成都市国学巷37号四川大学华西医院

Applicant address:

37 Guoxue Lane, Chengdu, Sichuan, China

Study leader's address:

37 Guoxue Lane, Chengdu, Sichuan, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

四川大学华西医院急诊科

Applicant's institution:

Emergency department of West China Hospital, Sichuan University

研究负责人所在单位:

四川大学华西医院

Affiliation of the Leader:

West China Hospital, Sichuan University

是否获伦理委员会批准:

否/No

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

四川大学华西医院

Primary sponsor:

West China Hospital, Sichuan University

研究实施负责(组长)单位地址:

四川省成都市国学巷37号

Primary sponsor's address:

37 Guoxue Lane, Chengdu, Sichuan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川省

市(区县):

成都市

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院

具体地址:

成都市国学巷37号

Institution
hospital:

West China Hospital, Sichuan University

Address:

37 Guoxue Lane

经费或物资来源:

四川省科技厅应对新型冠状病毒科技攻关应急项目(2020YFS0009)

Source(s) of funding:

Science and Technology Department of Sichuan Province (2020YFS0009)

Target disease:

COVID-19

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

1.分析新型冠状病毒感染病例的临床特征及危险因素。 2.与本团队前期建立的流感病毒感染病例数据库进行对比,探索早期鉴别的临床要点。 3.通过已知病例分析及参考现有循证证据,构建基于临床指标的新型冠状病毒感染病例临床风险预警模型(或评分)。 4.对模型的效度及信度进行验证。  

Objectives of Study:

1. To analyze the clinical features and risk factors of COVID-19 infected cases. 2. To explore the clinical key points of early differentiation between COVID-19 and influenza virus infection. 3. To establish a early warning score warning model based on clinical index. 4. Verify the validity and reliability of the model.

药物成份或治疗方案详述:

无 

Description for medicine or protocol of treatment in detail:

N/A 

纳入标准:

符合COVID-19疑似和确诊标准的患者。

Inclusion criteria

Patients who meet the suspected or confirmed diagnostic criteria of COVID-19.

排除标准:

Exclusion criteria:

N/A

研究实施时间:

Study execute time:

From 2020-01-01 00:00:00 To 2020-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-01-01 00:00:00 To 2020-12-31 00:00:00  

干预措施:

Interventions:

组别:

Case series

样本量:

1000

Group:

Case series

Sample size:

干预措施:

Nil

干预措施代码:

Intervention:

Nil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川省 

市(区县):

成都市 

Country:

China 

Province:

Sichuan 

City:

Chengdu 

单位(医院):

四川大学华西医院 

单位级别:

三甲医院 

Institution
hospital:

West China Hospital, Sichuan University

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

临床特征及危险因素

指标类型:

主要指标

Outcome:

clinical features and risk factors

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

效度及信度

指标类型:

主要指标

Outcome:

validity and reliability of the model

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 0 years
最大 Max age 100 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不涉及

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

N/A

Blinding:

N/A

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2021年1月31日

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Jan 31,2021

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-02-16 19:40:38